Remdesivir Use in the Setting of Severe Renal Impairment: A Theoretical Concern or Real Risk?

INTRODUCTION: Remdesivir (RDV) is FDA approved for COVID-19, but not recommended for patients with severe renal impairment (SRI, i.e. creatinine clearance < 30ml/min). Few studies have evaluated RDV in patients with SRI due to theoretical toxicity concerns. METHODS: Hospitalized patients receivin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Infect Dis
Main Authors: Pettit, Natasha N, Pisano, Jennifer, Nguyen, Cynthia T, Lew, Alison K, Hazra, Aniruddha, Sherer, Renslow, Mullane, Kathleen
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2020
Assuntos:
Major Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7799321/
https://ncbi.nlm.nih.gov/pubmed/33315065
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/cid/ciaa1851
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados